Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Silvia Dossena is active.

Publication


Featured researches published by Silvia Dossena.


Proceedings of the National Academy of Sciences of the United States of America | 2008

Functional assessment of allelic variants in the SLC26A4 gene involved in Pendred syndrome and nonsyndromic EVA

Alejandra Pera; Silvia Dossena; Simona Rodighiero; Marta Gandía; Guido Bottà; Giuliano Meyer; Felipe Moreno; Charity Nofziger; Concepción Hernández-Chico; Markus Paulmichl

Pendred syndrome is an autosomal recessive disorder characterized by sensorineural hearing loss, with malformations of the inner ear, ranging from enlarged vestibular aqueduct (EVA) to Mondini malformation, and deficient iodide organification in the thyroid gland. Nonsyndromic EVA (ns-EVA) is a separate type of sensorineural hearing loss showing normal thyroid function. Both Pendred syndrome and ns-EVA seem to be linked to the malfunction of pendrin (SLC26A4), a membrane transporter able to exchange anions between the cytosol and extracellular fluid. In the past, the pathogenicity of SLC26A4 missense mutations were assumed if the mutations fulfilled two criteria: low incidence of the mutation in the control population and substitution of evolutionary conserved amino acids. Here we show that these criteria are insufficient to make meaningful predictions about the effect of these SLC26A4 variants on the pendrin-induced ion transport. Furthermore, we functionally characterized 10 missense mutations within the SLC26A4 ORF, and consistently found that on the protein level, an addition or omission of a proline or a charged amino acid in the SLC26A4 sequence is detrimental to its function. These types of changes may be adequate for predicting SLC26A4 functionality in the absence of direct functional tests.


Journal of Molecular Endocrinology | 2009

Functional characterization of wild-type and mutated pendrin (SLC26A4), the anion transporter involved in Pendred syndrome

Silvia Dossena; Simona Rodighiero; Valeria Vezzoli; Charity Nofziger; Elisabetta Salvioni; Marta Boccazzi; Elisabeth Grabmayer; Guido Bottà; Giuliano Meyer; Laura Fugazzola; Paolo Beck-Peccoz; Markus Paulmichl

Pendred syndrome (PS) is the most frequent form of genetically related syndromic hearing loss, and is associated with mutations of pendrin, encoded by the SLC26A4 gene. This protein localizes to the cellular membrane and permits the exchange of anions between the cytosol and extracellular space. In the inner ear, pendrin conditions the endolymph, allowing for the proper function of sensory cells. Understanding the relationship between the genotype and phenotype of pendrin mutations would aid clinicians to better serve PS patients-however, little is known. Here, we summarize the available data concerning SLC26A4 mutations and how they relate to transporter function. The main findings suggest that all the truncation mutations tested annihilate pendrin function, and that the addition or omission of proline, or the addition or omission of charged amino acids in the sequence of SLC26A4 result in a substantial to dramatic reduction in pendrin function.


Nature Reviews Drug Discovery | 2013

Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective

Marc Maliepaard; Charity Nofziger; Marisa Papaluca; Issam Zineh; Yoshiaki Uyama; Krishna Prasad; Christian Grimstein; Michael A. Pacanowski; Falk Ehmann; Silvia Dossena; Markus Paulmichl

Pharmacogenetics, one of the cornerstones of personalized medicine, has the potential to change the way in which health care is offered by stratifying patients into various pretreatment categories, such as likely responders, likely non-responders or likely to experience adverse drug reactions. In order to advance drug development and regulatory science, regulatory agencies globally have promulgated guidelines on pharmacogenetics for nearly a decade. The aim of this article is to provide an overview of new guidelines for the implementation of pharmacogenetics in drug development from a multiregional regulatory perspective — encompassing Europe, the United States and Japan — with an emphasis on clinical pharmacokinetics.


Journal of Biological Chemistry | 2010

Calcium Oxalate Stone Formation in the Inner Ear as a Result of an Slc26a4 Mutation

Amiel A. Dror; Yael Politi; Hashem Shahin; Danielle R. Lenz; Silvia Dossena; Charity Nofziger; Helmut Fuchs; Martin Hrabé de Angelis; Markus Paulmichl; Steve Weiner; Karen B. Avraham

Calcium oxalate stone formation occurs under pathological conditions and accounts for more than 80% of all types of kidney stones. In the current study, we show for the first time that calcium oxalate stones are formed in the mouse inner ear of a genetic model for hearing loss and vestibular dysfunction in humans. The vestibular system within the inner ear is dependent on extracellular tiny calcium carbonate minerals for proper function. Thousands of these biominerals, known as otoconia, are associated with the utricle and saccule sensory maculae and are vital for mechanical stimulation of the sensory hair cells. We show that a missense mutation within the Slc26a4 gene abolishes the transport activity of its encoded protein, pendrin. As a consequence, dramatic changes in mineral composition, size, and shape occur within the utricle and saccule in a differential manner. Although abnormal giant carbonate minerals reside in the utricle at all ages, in the saccule, a gradual change in mineral composition leads to a formation of calcium oxalate in adult mice. By combining imaging and spectroscopy tools, we determined the profile of mineral composition and morphology at different time points. We propose a novel mechanism for the accumulation and aggregation of oxalate crystals in the inner ear.


Clinical Pharmacology & Therapeutics | 2011

STAT6 Links IL‐4/IL‐13 Stimulation With Pendrin Expression in Asthma and Chronic Obstructive Pulmonary Disease

Charity Nofziger; Valeria Vezzoli; Silvia Dossena; T Schönherr; J Studnicka; J Nofziger; Simone Vanoni; S Stephan; M E Silva; G. Meyer; Markus Paulmichl

Signaling through the interleukin‐4/interleukin‐13 (IL‐4/IL‐13) receptor complex is a crucial mechanism in the development of bronchial asthma and chronic obstructive pulmonary disease (COPD). In bronchial epithelial cells, this signaling pathway leads to changes in the expression levels of several genes that are possibly involved in protection against and/or pathogenesis of these diseases. The expression of pendrin (SLC26A4), a candidate for the latter category, is upregulated by IL‐4/IL‐13 and leads to overproduction of mucus and increased viscosity of the airway surface liquid (ASL). Therefore, elucidating the transcriptional regulation of pendrin could aid in the development of new pharmacological leads for asthma and/or COPD therapy. Here we show that IL‐4/IL‐13 significantly increased human pendrin promoter activity in HEK‐Blue cells but not in STAT6‐deficient HEK293 Phoenix cells; that mutation of the STAT6 binding site (N4 GAS motif) rendered the promoter insensitive to IL‐4/IL‐13; and that addition of the N4 GAS motif to an IL‐4/IL‐13‐unresponsive sequence of the human pendrin promoter conferred sensitivity to both ILs.


Trends in Pharmacological Sciences | 2015

Targeting SREBPs for treatment of the metabolic syndrome.

Selma M. Soyal; Charity Nofziger; Silvia Dossena; Markus Paulmichl; Wolfgang Patsch

Over the past few decades, mortality resulting from cardiovascular disease (CVD) steadily decreased in western countries; however, in recent years, the decline has become offset by the increase in obesity. Obesity is strongly associated with the metabolic syndrome and its atherogenic dyslipidemia resulting from insulin resistance. While lifestyle treatment would be effective, drugs targeting individual risk factors are often required. Such treatment may result in polypharmacy. Novel approaches are directed towards the treatment of several risk factors with one drug. Studies in animal models and humans suggest a central role for sterol regulatory-element binding proteins (SREBPs) in the pathophysiology of the metabolic syndrome. Four recent studies targeting the maturation or transcriptional activities of SREBPs provide proof of concept for the efficacy of SREBP inhibition in this syndrome.


Cellular Physiology and Biochemistry | 2011

Identification of Allelic Variants of Pendrin (SLC26A4) with Loss and Gain of Function

Silvia Dossena; Aigerim Bizhanova; Charity Nofziger; Emanuele Bernardinelli; Josef Ramsauer; Peter Kopp; Markus Paulmichl

Background: Pendrin is a multifunctional anion transporter that exchanges chloride and iodide in the thyroid, as well as chloride and bicarbonate in the inner ear, kidney and airways. Loss or reduction in the function of pendrin results in both syndromic (Pendred syndrome) and non-syndromic (non-syndromic enlarged vestibular aqueduct (ns-EVA)) hearing loss. Factors inducing an up-regulation of pendrin in the kidney and the lung may have an impact on the pathogenesis of hypertension, chronic obstructive pulmonary disease (COPD) and asthma. Here we characterize the ion transport activity of wild-type (WT) pendrin and seven of its allelic variants selected among those reported in the single nucleotide polymorphisms data base (dbSNPs), some of which were previously identified in a cohort of individuals with normal hearing or deaf patients belonging to the Spanish population. Methods: WT and mutated pendrin allelic variants were functionally characterized in a heterologous over-expression system by means of fluorometric methods evaluating the I-/Cl- and Cl-/OH- exchange and an assay evaluating the efflux of radiolabeled iodide. Results: The transport activity of pendrin P70L, P301L and F667C is completely abolished; pendrin V609G and D687Y allelic variants are functionally impaired but retain significant transport. Pendrin F354S activity is indistinguishable from WT, while pendrin V88I and G740S exhibit a gain of function. Conclusion: Amino acid substitutions involving a proline always result in a severe loss of function of pendrin. Two hyperfunctional allelic variants (V88I, G740S) have been identified, and they may have a contributing role in the pathogenesis of hypertension, COPD and asthma.


Cellular Physiology and Biochemistry | 2011

Molecular and Functional Characterization of Human Pendrin and its Allelic Variants

Silvia Dossena; Charity Nofziger; Grazia Tamma; Emanuele Bernardinelli; Simone Vanoni; Christoph Nowak; Elisabeth Grabmayer; Sonja Kössler; Susanne Stephan; Wolfgang Patsch; Markus Paulmichl

Pendrin (SLC26A4, PDS) is an electroneutral anion exchanger transporting I -, Cl -, HCO3-, OH -, SCN - and formate. In the thyroid, pendrin is expressed at the apical membrane of the follicular epithelium and may be involved in mediating apical iodide efflux into the follicle; in the inner ear, it plays a crucial role in the conditioning of the pH and ion composition of the endolymph; in the kidney, it may exert a role in pH homeostasis and regulation of blood pressure. Mutations of the pendrin gene can lead to syndromic and non-syndromic hearing loss with EVA (enlarged vestibular aqueduct). Functional tests of mutated pendrin allelic variants found in patients with Pendred syndrome or non-syndromic EVA (ns-EVA) revealed that the pathological phenotype is due to the reduction or loss of function of the ion transport activity. The diagnosis of Pendred syndrome and ns-EVA can be difficult because of the presence of phenocopies of Pendred syndrome and benign polymorphisms occurring in the general population. As a consequence, defining whether or not an allelic variant is pathogenic is crucial. Recently, we found that the two parameters used so far to assess the pathogenic potential of a mutation, i.e. low incidence in the control population, and substitution of evolutionary conserved amino acids, are not always reliable for predicting the functionality of pendrin allelic variants; actually, we identified mutations occurring with the same frequency in the cohort of hearing impaired patients and in the control group of normal hearing individuals. Moreover, we identified functional polymorphisms affecting highly conserved amino acids. As a general rule however, we observed a complete loss of function for all truncations and amino acid substitutions involving a proline. In this view, clinical and radiological studies should be combined with genetic and molecular studies for a definitive diagnosis. In performing genetic studies, the possibility that the mutation could affect regions other than the pendrin coding region, such as its promoter region and/or the coding regions of functionally related genes (FOXI1, KCNJ10), should be taken into account. The presence of benign polymorphisms in the population suggests that genetic studies should be corroborated by functional studies; in this context, the existence of hypo-functional variants and possible differences between the I -/Cl - and Cl -/HCO3- exchange activities should be carefully evaluated.


Cellular Physiology and Biochemistry | 2006

Fast Fluorometric Method for Measuring Pendrin (SLC26A4) Cl-/I- Transport Activity

Silvia Dossena; Simona Rodighiero; Valeria Vezzoli; Claudia Bazzini; Chiara Sironi; Giuliano Meyer; Johannes Fürst; Markus Ritter; Maria Lisa Garavaglia; Laura Fugazzola; Luca Persani; Patrick Zorowka; Carlo Storelli; Paolo Beck-Peccoz; Guido Bottà; Markus Paulmichl

Malfunction of the SLC26A4 protein leads to Pendred syndrome, characterized by sensorineural hearing loss, often associated with mild thyroid dysfunction and goiter. It is generally assumed that SLC26A4 acts as a chloride/anion exchanger, which in the thyroid gland transports iodide, and in the inner ear contributes to the conditioning of the endolymphatic fluid. Here we describe a fast fluorometric method able to be used to functionally scrutinize SLC26A4 and its mutants described in Pendred syndrome. The validation of the method was done by functionally characterizing the chloride/iodide transport of SLC26A4, and a mutant, i.e. SLC26A4S28R, which we previously described in a patient with sensorineural hearing loss, hypothyroidism and goiter. Using the fluorometric method we describe here we can continuously monitor and quantify the iodide or chloride amounts transported by the cells, and we found that the transport capability of the SLC26A4S28R mutant protein is markedly reduced if compared to wild-type SLC26A4.


Cellular Physiology and Biochemistry | 2006

Functional Characterization of Wild-Type and a Mutated Form of SLC26A4 Identified in a Patient with Pendred Syndrome

Silvia Dossena; Valeria Vezzoli; Nadia Cerutti; Claudia Bazzini; M. Tosco; Chiara Sironi; Simona Rodighiero; Giuliano Meyer; Umberto Fascio; Johannes Fürst; Markus Ritter; Laura Fugazzola; Luca Persani; Patrick Zorowka; Carlo Storelli; Paolo Beck Peccoz; Guido Bottà; Markus Paulmichl

Background: Malfunction of the SLC26A4 protein leads to prelingual deafness often associated with mild thyroid dysfunction and goiter. It is assumed that SLC26A4 acts as a chloride/anion exchanger responsible for the iodide organification in the thyroid gland, and conditioning of the endolymphatic fluid in the inner ear. Methods: Chloride uptake studies were made using HEK293-Phoenix cells expressing human wild type SLC26A4 (pendrin) and a mutant (SLC26A4S28R) we recently described in a patient with hypothyroidism, goiter and sensorineural hearing loss. Results: Experiments are summarized showing the functional characterization of wild type SLC26A4 and a mutant (S28R), which we described recently. This mutant protein is transposed towards the cell membrane, however, its transport capability is markedly reduced if compared to wild-type SLC26A4. Furthermore, we show that the SLC26A4 induced chloride uptake in HEK293-Phoenix cells competes with iodide, and, in addition, that the chloride uptake can be blocked by NPPB and niflumic acid, whereas DIDS is ineffective. Conclusions: The functional characteristics of SLC26A4S28R we describe here, are consistent with the clinical phenotype observed in the patient from which the mutant was derived.

Collaboration


Dive into the Silvia Dossena's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Johannes Fürst

Innsbruck Medical University

View shared research outputs
Top Co-Authors

Avatar

Wolfgang Patsch

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge